Form 8-K - Current report:
SEC Accession No. 0000318154-24-000018
Filing Date
2024-05-02
Accepted
2024-05-02 16:03:58
Documents
16
Period of Report
2024-05-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amgn-20240502.htm   iXBRL 8-K 43962
2 EX-99.1 EARNINGS RELEASE amgn-20240331earningsrelea.htm EX-99.1 501820
7 GRAPHIC amgenlogo.jpg GRAPHIC 13030
  Complete submission text file 0000318154-24-000018.txt   782262

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amgn-20240502.xsd EX-101.SCH 3083
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT amgn-20240502_def.xml EX-101.DEF 17248
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amgn-20240502_lab.xml EX-101.LAB 30309
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amgn-20240502_pre.xml EX-101.PRE 17599
19 EXTRACTED XBRL INSTANCE DOCUMENT amgn-20240502_htm.xml XML 4509
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 24908054
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)